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Summary  21 
Aim: To assess the properties of a medical device containing xyloglucan, propolis 22 
and hibiscus to create a bio-protective barrier to avoid the contact of urophatogenic E. 23 
coli (UPEC) strains on cell walls in models of intestinal (CacoGoblet) and uroepithelial 24 
(RWPE-1) cells. 25 
Materials & methods: Two UPEC strains (expressing type 1 fimbriae and P 26 
fimbriae) were used to assess by electronic microscopy and ELISA the barrier 27 
properties of the medical device. The antimicrobial activity was assessed in broth 28 
dilution assays.  29 
Results: The three components (xyloglucan, propolis and hibiscus) did not alter E. 30 
coli cell integrity in intestinal and uroepithelial cell models and were devoid of 31 
antibacterial activity. The three components avoided bacterial contact in both cell 32 
monolayers.  33 
Conclusion: The non-pharmacological barrier properties of xyloglucan, propolis and 34 
hibiscus confirm the role of the medical device for the management of UTIs.  35 
 36 
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1. INTRODUCTION 41 
Urinary tract infections (UTIs) are one of the most prevalent infectious diseases and, 42 
in consequence, a widespread health problem, with economical and health care 43 
consequences [1-3], mainly affecting women, but also patients with catheters, diabetes, 44 
immunodeficiency syndromes, underlying urologic abnormalities, and children [4,5]. 45 
The primary causative agents of UTIs, accounting for greater than 80% of these 46 
infections, are strains of uropathogenic Escherichia coli (UPEC) [6], the majority of 47 
which ascend from the intestine through the urethra and the bladder and, sometimes, to 48 
the kidneys [7].  49 
After colonization, the next step in the pathogenesis of a UTI is the adhesion of 50 
uropathogens to the epithelial bladder cells. Following adherence, uropathogens are 51 
protected from removal by micturition. The adhesion of E. coli to the uroepithelial cell 52 
receptors of the host is accomplished by hair-like organelles called fimbriae. The most 53 
important are type 1 fimbriae and P-fimbriae. Type 1 fimbriae mainly play a role in the 54 
pathogenesis of cystitis and P-fimbriae in pyelonephritis [6,7]. 55 
Individuals prescribed an antibiotic for a UTI in primary care acquire bacterial 56 
resistance to that antibiotic [8]. The WHO global surveillance report highlights an 57 
increase in bacterial resistance to fluoroquinolones used to treat UTIs (ineffective in 58 
more than 50% of cases in some countries [9]. 59 
The alarming increase in antimicrobial resistance is a global threat to future 60 
treatment of infections and has stimulated interest in non-antibiotic prophylaxis of 61 
recurrent UTIs [1,5,7,10]. 62 
 63 
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In this regard, non-pharmacological oral supplements, including cranberry 64 
proanthocyanidins [11-13], probiotics [14] and a medical device containing a mucosal 65 
protector -as xyloglucan or reticulated protein-, hibiscus and propolis) [1,10,15], have 66 
been evaluated for the prevention of UTIs. Although it is recognized that more research 67 
is needed, the use of non-pharmacological products to prevent UTIs should be 68 
considered a useful and safe alternative to antibiotics in this era of increasing antibiotic 69 
resistance [10,14]. 70 
The medical device containing xyloglucan, hibiscus and propolis (Novintethical 71 
Pharma, SA, Switzerland) is a non-pharmacological oral supplement that was approved 72 
recently for the prevention of UTIs. It contains xyloglucan (a natural hemicellulose) as 73 
the main ingredient, along with the natural products propolis and Hibiscus sabdariffa, 74 
known with urinary protective properties and to have a role in preventing UTIs [1,15-75 
17]. Xyloglucan belongs to a new class of products, defined as “mucosal protectors”, 76 
which form a bio-protective film, restoring the physiological functions of the intestinal 77 
walls. Results of recent clinical studies have shown that the administration of 78 
xyloglucan is a fast, efficacious and safe option for the treatment of acute diarrhea in 79 
adults and children [18,19]. 80 
The rationale for the potential preventive action of the medical device in UTIs is 81 
based on the protective properties of the ingredients in the intestine to avoid the 82 
adhesivity of E. coli in the “intestinal reservoir” [10,20], the first step of uropathogenic 83 
E. coli proliferation which is followed by bacterial migration from the intestinal tract to 84 
the perineal region and, therefore, to the urinary tract [10,21-23]. We have also the 85 
hypothesis that the components of the medical device are also able to create a barrier 86 
that avoids the contact of UPEC on the cells of the urinary tract.  87 
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In previous in vitro studies, we demonstrated in a model of intestinal mucosa (Caco-88 
2 and CacoGobletTM cells) that this medical device (1.5 to 10 mg/mL) protected cell 89 
tight junctions and protected cells from E. coli intracellular invasion, being the first step 90 
for the demonstration of the efficacy of this product to prevent UTIs [10]. 91 
In a recent randomized, double-blind, placebo-controlled clinical trial in 60 patients 92 
with one or more symptoms of UTIs (dysuria, urgency, suprapubic pain and/or urine 93 
organoleptic changes), the administration of a similar medical device (containing 94 
reticulated protein, hibiscus and propolis) twice daily for 5 days provided greater 95 
symptom relief than placebo, with a lower risk ratio of patients needing antibiotic 96 
treatment than placebo [1]. In an another double-blind, placebo-controlled clinical trial 97 
in adult women with recurrent uncomplicated cystitis, the administration of 1 capsule of 98 
the medical device/day during antibiotic treatment and during 2 months post-antibiotic 99 
treatment significantly reduced the symptomatic recurrence (by 19.4%) in comparison 100 
with placebo (p = 0.015), with no recurrence being observed after the first month of 101 
follow-up [15]. 102 
In this context, the present in vitro study has been designed to assess the barrier 103 
properties of the ingredients of the medical device (xyloglucan, propolis and hibiscus) 104 
against adhesion of UPEC strains in a model of intestinal (CacoGobletTM cells) and 105 
uroepithelial cells (RWPE-1 cells), by means of electronic microscopy and ELISA 106 
assays, to demonstrate the mechanism of action of the medical device in preventing 107 
UTIs, at both intestine and urinary tract.  108 
 109 
2. MATERIALS AND METHODS 110 
 6 
2.1. Ingredients of the medical device 111 
We evaluated the effects of the ingredients of the medical device: xyloglucan, 112 
extracted from the seeds of the tamarind tree (Tamarindus indica) and extracts of 113 
Hibiscus sabdariffa and propolis. These ingredients were kindly provided by 114 
Novintethical Pharma, SA, and diluted in phosphate buffer solution. 115 
We assessed the range of concentrations from 1 to 10 mg/ml for the extracts of 116 
Hibiscus sabdariffa and propolis, exceeding the maximum possible concentrations of 117 
these ingredients in the intestine, faeces or urine that can be achieved with the 118 
administration of the product studied. In the case of xyloglucan, given that 200 mg/day 119 
can be administered and nothing is absorbed, the concentrations obtained in colon and 120 
faeces are from 0.13 to 1 mg/ml. In this case, the range of 1 to 10 mg/ml was also 121 
studied. 122 
 123 
2.2. Bacterial strains  124 
Two UPEC strains from the Culture Collection of University of Göteborg (CCUG) 125 
collection were used: E. coli expressing type 1 fimbriae (nº 12 from CCUG) and E. coli 126 
expressing P fimbriae (nº 41 from CCUG).  127 
Bacteria used in the antibacterial activity assay were: E. coli (the two strains from 128 
CCUG), Pseudomonas aeruginosa (CECT111), Staphylococcus aureus (CECT240) and 129 
Enterococcus faecalis (CECT481). 130 
2.3. Cells and reagents 131 
CacoGobletTM (Readycell, Spain) cells were used for the intestinal mucosa model. 132 
Caco-2 and human goblet mucus secreting cells were seeded at a density of 1.5×105 133 
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cells/well on 0.4 µM PET transwell inserts (Millipore) in 12-well plates and maintained 134 
for 21 days. Cells became confluent at day 6 and reached steady state at day 10. Cellular 135 
differentiation was completed at day 21. Microvilli and tight junctions were visible by 136 
microscopy during cellular differentiation.  137 
 138 
CacoGoblet cells were maintained in DMEM medium with high glucose (Dulbecco’s 139 
modified Eagle medium, Lonza, Belgium) supplemented with 10% fetal bovine serum 140 
(FBS, Lonza, Belgium), 1% Non-Essential Amino Acid (NEAA, Lonza, Belgium), 4 141 
mM glutamine (Lonza, Belgium), 10 mM hepes (Lonza, Belgium) and 1% penicillin-142 
streptomycin (Lonza, Belgium), at 37ºC, 90% humidity and 5% CO2. 143 
 144 
RWPE-1 cells (ATTC® CRL-11609TM), derived from normal human prostate 145 
epithelium, were used as an uroepithelial model. Cells were seeded at a density of 146 
2.4×104 cells/well on 0.4 µM PET transwell inserts (Millipore) in 24-well plates and 147 
maintained for 7 days to obtain cell confluence. 148 
RWPE-1 cells were maintained in complete KSFM supplemented with 50 µg/ml 149 
BPE, 5 ng/ml EGF and 1% antibiotic/antimycotic mixture.  150 
All assays were performed at neutral pH (7.3).  151 
2.4. Adherence assays 152 
Confluent cell layers in 24-well plates were used. Prior to infection, cells were treated 153 
with the three ingredients (extract of Hibiscus sabdariffa, extract of propolis or 154 
xyloglucan) for 1.5 h at 37ºC, 5% CO2 and 90% humidity. Bacteria at a final 155 
concentration of 105/ml were then added and cultures were incubated at 37ºC for 2 h to 156 
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allow bacteria to adhere. Non-adherent bacteria were then removed by washing the cells 157 
two times with PBS. A MOI (multiplicity of infection) of 100 bacteria per eukaryotic 158 
cell was used.  159 
Untreated confluent cell layers with and without bacteria were used as controls. All 160 
experiments were performed in triplicates.  161 
 162 
2.5. Scanning Electronic Microscopy (SEM) 163 
Samples for SEM had to be dry and conductive. The drying process was carried out 164 
preserving the original structure of the sample as far as possible and the sample was 165 
coated afterwards with a material that made the sample conductive and allowed it to be 166 
observed under the microscope. 167 
After removal of non-adherent bacteria (see above), 2.5% glutaraldehyde in PBS was 168 
added and the plate was incubated for 1h in cold. The whole plate was washed twice 169 
more with PBS and then put to incubate in PBS in the refrigerator for 0.5 h. The whole 170 
plate was washed twice more with PBS and 70% ethanol was added, incubating for 0.5 171 
h at room temperature. Lastly, dehydration was continued to absolute ethanol. 172 
The next day, samples were critical-point dried and then, once mounted on supports 173 
for transmission electron microscopy, metallised with gold/palladium. Samples were 174 





2.6. Bacterial quantification 179 
For each variable, 20 fields were counted, with 10 euckaryotic cells per field (a total of 180 
200 cells per variable). Bacterial count was analysed directly by SEM.  181 
Quantification of bacteria (E. coli expressing type 1 fimbriae and expressing P 182 
fimbriae) in the adherence assays with RWPE-1 cells were also performed using 183 
Enzyme-Linked ImmunoSorbent Assay (ELISA) using a polyconal IgG antibody 184 
against E. coli O and K antigens (Anti Escherichia coli Antibody, Polyclonal IgG-185 
Biorad 4329-4911, Bio-Rad Laboratories SA, Alcobendas, Spain) diluted 1/200 in PBS. 186 
Streptavidin-peroxidase from Streptomyces avidinni (Sigma Aldrich Química SA, Tres 187 
Cantos, Madrid, Spain) was used as a secondary reagent for the detection of 188 
biotinylated antibodies diluted 1/1000 in PBS. Finally, the chromogenic substrate for 189 
peroxidise 2,2′-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) (Sigma 190 
Aldrich Química SA, Tres Cantos, Madrid, Spain) was used and detected at an 191 
absorbance of 405 nm.  192 
 193 
Before the immunological reaction, cells were ethanol fixed (70%) and endogenous 194 
peroxidases were deactivated with 3% H2O2 in 1x PBS for 10 min. Non-specific 195 
reactivity was blocked by adding 10% Fetal Bovine Serum(FBS) in PBS.  196 
 197 
2.7. Antibacterial activity assay 198 
Ingredients were tested for potential antimicrobial activity (bactericidal and 199 
bacteriostatic) with the broth dilution assay, using two different culture media, Mueller-200 
Hinton broth and Luria Bertaina (LB). Bacteria tested were E. coli, Pseudomonas 201 
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aeruginosa, Staphylococcus aureus and Enterococcus faecalis (4 strains of each), at a 202 
final inoculum of 105 CFU/ml.  203 
Ingredients were dissolved and diluted with culture broth at different concentrations. 204 
Hibiscus extract was used at concentrations of 2%, 1% and 0.5%; propolis extrat at 205 
0.6%, 0.3% and 0.175% and xyloglucan at 0.5%, 0.25% and 0.125%. 206 
Then, each tube was inoculated with a microbial inoculums prepared in the same 207 
medium at 108 CFU/ml, at a proportion of 1:1000 (inoculum : total volume) to obtain a 208 
bacterial concentration of 105 CFU/ml. After well-mixing, the inoculated tubes were 209 
incubated at 37ºC during 24 hours. Inoculated tubes without the ingredients were used 210 
as positive controls and non inoculated tubes containing the ingredients were used as 211 
negative controls.  212 
Monitoring of growth was performed by measuring absorbance at 600 nm.  213 
 214 
 215 
2.8. Statistical analysis 216 
A descriptive analysis of quantitative data was performed (mean and standard 217 
deviation were obtained). The Student´s T-test was used to compare results between 218 
two conditions. P values lower than 0.05 were considered significant.  219 
 220 
3. RESULTS 221 
3.1. Xyloglucan, propolis and hibiscus are not endowed with antibacterial activity 222 
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In the different cell models assessed (CacoGoblet and RWPE-1), we observed that 223 
the three components, separately assessed at the maximum concentrations (10 mg/ml 224 
for xyloglucan and propolis and 1 mg/ml for hibiscus), did not alter E. coli cell 225 
integrity, without evidences of bacterial lysis in both bacterial strains assessed (E. coli 226 
expressing type 1 fimbriae and expressing P fimbriae) (Figures 1A [1-3] and 1B [1-4]). 227 
In the case of E. coli expressing type P fimbriae incubated treated with hibiscus (1 228 
mg/ml) (figure 1B-3) and propolis (10 mg/ml) (figure 1B-4) it seems that the cellular 229 
membranes have some irregularities. We consider that in the first case (figure 1B-3) it is 230 
due to the deposition of material and, in the second (figure 1B-4), the left part of the 231 
membrane is completely normal and the right must be partially disrupted (by the SEM 232 
electrons, it is not well focused). In both cases, morphological characteristics and shape 233 
are preserved. 234 
The absence of antimicrobial activity of xyloglucan, propolis and hibiscus was also 235 
confirmed in the antibacterial activity tests. At all concentrations assessed for the three 236 
components, no effect on the bacterial growth was observed, for all bacteria evaluated 237 
(E. coli, Pseudomonas aeruginosa, Staphylococcus aureus and Enterococcus faecalis). 238 
The presence of the three components did not interfer the growth of these bacteria 239 
during an incubation period of 24h at 37ºC, with similar absorbances at 600 nm than 240 
controls without components.  241 
These results confirm the absence of pharmacological bactericidal or bacteriostatic 242 
activity of the three components of the medical device.  243 
 244 
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3.2. The components of the medical device avoids bacterial adhesion on cell 245 
monolayers 246 
By means of observation by SEM, both UPEC strains assessed adhered perfectly to the 247 
surface of CacoGoblet and RWPE-1 cells (Figures 2A-F). In RWPE-1 cells we 248 
observed adhesion of E. coli strains at a higher extent, with the formation of biofilms 249 
and adhesion at cytoplasmic level and in on the cell expansions (Figures 3A and B).  250 
With the addition of xyloglucan, at 1 and 10 mg/ml, practically no bacteria were seen 251 
adhered to the cell surface (Figures 4A-D). In the case of hibiscus and propolis extracts, 252 
we also observed a reduction of adhesion, particularly at the highest concentrations 253 
(Figures 5A-D).  254 
In both cell cultures, a statistically significant reduction of the number of cell adhered 255 
(for both E. coli strains) were observed for the three components in comparison with 256 
controls (p < 0.05). The reduction was also more important at the highest concentration 257 
of the components (Table 1). The highest reduction of adhesion was observed with 258 
hibiscus at 10 mg/ml (Table 1).  259 
We also detected an important reduction of bacterial adhesion in RPWE-1 cells assessed 260 
by ELISA, particularly at the highest concentration of xyloglucan, hibiscus and propolis 261 
(10 mg/ml) (Absorbances for xyloglucan, hibiscus and propolis: 0.3740, 0.2116 and 262 
0.318 vs 0.8796 from the positive control) (Table 2).  263 
 264 
DISCUSSION 265 
Nowadays, in the advent of increasing bacterial resistance, prescription of preventive 266 
measures to avoid recurrent UTIs, particularly in risk groups, as women or children, 267 
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represents a priority in the routine clinical practice [10,24,25]. Preventive goals include 268 
identification of any correctible anatomical or functional predisposing aberrations, 269 
hygiene measures, diet and food supplements as non-antibiotic method of prevention 270 
[24,25].  271 
In this regard, the medical device from Novintethical Pharma SA, Switzerland, is a 272 
non-pharmacological oral supplement recently approved for the prevention of UTIs, 273 
containing xyloglucan, propolis and Hibiscus sabdariffa, known with urinary protective 274 
properties and to have a role in preventing UTIs [1,16,17]. 275 
In a recent double-blind, placebo-controlled clinical trial in 60 adult patients with 276 
symptoms of UTI, the administration of a similar medical device twice daily for 5 days 277 
significantly reduced the need of antibiotic treatment in comparison with placebo. 278 
Moreover, the administration of the oral supplement was associated with an 279 
improvement of all the UTI symptoms/signs, including dysuria, urgency, suprapubic 280 
pain and organoleptic changes. These results clearly highlight the role of the medical 281 
device as an adjuvant non-pharmacological measure in patients with or at risk of UTIs 282 
[1]. Moreover, in women with recurrent cystitis, the administration of the medical 283 
device has been shown to significantly reduce the rate of recurrences, a common 284 
situation that deserves the use of preventive measures as the administration of non-285 
pharmacological products [15]. 286 
In this context, the results of the present in vitro study have demonstrated the non-287 
pharmacological nature of the three components xyloglucan, propolis and hibiscus, 288 
devoid of antibiotic activity (in both microscopic and antibacterial activity assays). We 289 
have also demonstrated that the three components are able to create a physical 290 
bioprotective film that is able to avoid the contact of UPEC strains in a model of 291 
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intestinal mucosal cells (CacoGobletTM cells) and uroepithelial cells (RWPE-1 cells), 292 
thus supporting their role in two key steps in the pathogenesis of UTIs: avoiding the 293 
persistence of UPEC reservoirs in the lower intestinal tract [10,21-23] and avoiding the 294 
urogenital colonization of UPEC, interfering in the process by which uropathogens 295 
contact with uroepithelial cell receptors [7].  296 
 297 
It is known that uropathogenic E. coli, the primary causative agent of UTIs, can 298 
adhere to the uroepithelial cells through adhesive organelles, including type 1, P, and S 299 
pili along with Dr adhesins, promoting both bacterial attachment to and invasion of host 300 
tissues within the urinary tract. This can provide E. coli with a survival advantage, 301 
allowing the microbes to better resist detection and clearance by both innate and 302 
adaptive immune defence mechanisms [6].  303 
Type 1 and P fimbriae are the most important virulence factor associated to 304 
adherence to uroephitelial cells, acting synergistically to facilitate bacterial colonization 305 
[26]. They bind to mono-mannose and globoseries glycosphingolipids, respectively 306 
[27,28], with similar structures arranged in two distinct subassemblies, the tip fibrillum 307 
and the pilus rod (more simplified in the case of type 1 fimbriae [29].  308 
It has been recently shown that P fimbriae mediate binding between the bacteria and 309 
the epithelial cells lining the tubules, while type 1 fimbriae appears to play a role in 310 
inter-bacterial binding and biofilm formation in the center parts of the lumen [26]. 311 
In any case, our results have demonstrated that the presence of components of the 312 
medical device is able to interfere in both colonization mechanisms. 313 
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Therefore, the interference with adhesion observed in our study in the RWPE-1 cell 314 
line, a widely used and reproducible model of urinary cells [30-34], indicates the main 315 
mechanism by which the medical device is able to avoid UPEC colonization and further 316 
invasion, in consonance with the favourable results observed in patients with UTIs with 317 
similar products [1,15]. RWPE-1 are non-neoplastic adult human prostatic epithelial 318 
cells, which, in contrast with urinary neoplastic cell lines (as bladder, ureter or renal 319 
pelvic cells), are being more easily cultured.  320 
 321 
Moreover, the avoidance of adhesion also observed in CacoGobletTM cells (Co-322 
cultured Caco-2 cells and human goblet mucus secreting cells, a better mimicking of the 323 
intestine versus Caco-2 monolayer) [10] also confirm the utility of the medical device to 324 
reduce UPEC reservoirs at intestinal level, in consonance with previous recent studies 325 
in which we observed that the product created a protective physical barrier on 326 
CacoGobletTM cells, protecting cell tight junctions and protecting intestinal cells from 327 
E. coli intracellular invasion [10].  328 
In the present study we have also observed that xyloglucan is also able to create this 329 
protective barrier in a model of urinary cells, and also propolis and hibiscus exerts this 330 
effect. Since propolis and hibiscus are systemically absorbed, they can exert these 331 
protective effects directly in the urinary tract, thus preventing the attachment of possible 332 
uropathogenic bacteria, and, in consequence, the occurrence of UTIs. In the case of 333 
xyloglucan, since it is not absorbed, we consider that its protective effects are mainly 334 
exerted on the intestinal tract.  335 
 336 
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Therefore, our results support the role of hibiscus and propolis in the prevention of 337 
UTIs, in line with the popular knowledge and previous experience of these natural 338 
products related to UTIs [16,17].  339 
Propolis is a resinous material collected by bees from exudates and buds of plants, 340 
then mixed with wax and bee enzymes. In a double-blind, randomized, cross-over 341 
clnical trial in 5 volunteers, the propolis excreted in urine after once daily 342 
administration together with cranberry produced a significant bacterial anti-adhesion 343 
activity in comparison with placebo in a human T24 epithelial cell-line assay and in the 344 
in vivo Caenorhabditis elegans model, thus supporting the use of propolis as adjuvant to 345 
prevent recurrent UTIs [16].  346 
Moreover, in previous studies, it has been shown that extracts of Hibiscus sabdariffa 347 
are able to inhibit biofilm production of urinary isolates of Candida albicans, thus 348 
supporting its anti-adhesive properties at urinary level [17].  349 
 350 
In this context, our results confirm the capacity of the component of the medical device 351 
to form a protective barrier on the urinary tract. Based on this, further clinical studies 352 
could be done to assess the preventive effect of the medical device to prevent UTIs in 353 
patients at risk of recurrent UTIs. The use of the medical device to prevent catheter-354 
associated UTIs (CAUTIs) could be also considered, taking in to account the high 355 
prevalence of these infections [35] and that, in most cases, CAUTIs are caused by 356 
microorganisms from the patient´s own gastrointestinal tract [36].  357 
 358 
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In conclusion, we have demonstrated the non-pharmacological barrier properties of 359 
the components of the medical device on intestinal and uroepithelials cell models, thus 360 
confirming the role of this product for the management of UTIs in the routine clinical 361 
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EXECUTIVE SUMMARY 372 
1. A non-pharmacological oral medical device which was approved recently for the 373 
prevention of UTIs, containing xyloglucan (a natural hemicellulose), propolis 374 
and hibiscus. 375 
2. Xyloglucan belongs to a new class of products, defined as “mucosal protectors”, 376 
which form a bio-protective film, restoring the physiological functions of the 377 
intestinal and uroepithelial walls. 378 
3. This in vitro study evaluated the effects of the three components avoiding UPEC 379 
adherence on intestinal (CacoGoblet) and uroepithelial (RWPE-1) cells. 380 
4. Xyloglucan, propolis and hibiscus did not exhibit antibacterial effects on both 381 
cell models and in broth dilution assays, thus confirming the absence of 382 
pharmacological effect.  383 
5. Xyloglucan, propolis and hibiscus avoided the adherence of two UPEC strains 384 
on intestinal and uroepithelial cells.  385 
6. The observed effects of xyloglucan, propolis and hibiscus support the use of the 386 
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xyloglucan* hibiscus* propolis*  
  1 mg/ml 10 mg/ml 1 mg/ml 10 mg/ml 1 mg/ml 10 mg/ml  
E. coli expressing type 1 fimbriae  
Caco 
Goblet 
42.32 ±7.374 5.22 ±1.940 4.1±1.644 4.6±1.826 3.72±1.591 4.72±1.714 4.0±1.784 
RPWE-1 31.44 ±7.085 5.8±1.948 5.04±1.958 4.82± .534 4.08±1.482 4.72±1.471 3.88±1.303 
E. coli expression P fimbriae 
Caco 
Goblet 
28.92 ± 7.286 3.2 ± 1.142 2.29±0.804 3.44±1.264 2.48±0.788 3.52±1.232 2.6±0.833  
RPWE-1 26.86 ± 6.269 2.94 ±0.998 2.54±0.885 3.16±1.218 2.44±0.951 3.32±1.114 2.52±0.886  
 
*p < 0.05 in comparison with positive control 513 
 514 
Table 2. Adherence quantification by ELISA (absorbance) (E. coli expressing type 515 






xyloglucan* hibiscus* propolis* negative 
control 
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FIGURE LEGENDS 522 
Figure 1. Effect of the separated three components (10 mg/ml for xyloglucan and 523 
propolis and 1 mg/ml for hibiscus), over E. coli cell integrity: without evidence of 524 
bacterial lysis in both bacterial strains. 1A-1 to 3 and 1B-1 to 4. 525 
    526 
Figures 1A-1 (control E. coli expressing type 1 fimbriae); 1A-2 and 1A-3 (Effect of 527 
xyloglucan 10 mg/ml and hibiscus 10 mg/ml over E. coli expressing type 1 fimbriae. 528 
    529 
Figures 1B-1 (control E. coli expressing type P fimbriae); 1B-2, 1B-3 and 1B-4 (Effect 530 
of xyloglucan 1 mg/ml, hibiscus 1 mg/ml and propolis 10 mg/ml over E. coli expressing 531 







1B-1 1B-2 1B-3 1B-4 
1A-2 1A-3 
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Figures 2. Adhesion of UPEC strains to CacoGoblet and RWPE-1 cells. 2A) Adhesion 538 
of E. coli expressing type 1 fimbriae to CacoGoblet. 2B) Adhesion of E. coli expressing 539 
type 1 fimbriae on RWPE-1 cells. 2C) Adhesion of E. coli expressing P fimbriae on 540 
CacoGoblet. 2D) Adhesion of E. coli expressing P fimbriae on RWPE-1 cells. 2E) 541 
CacoGoblet cells (without bacterial strains). 2F) RWPE-1 cells (without bacterial 542 
strains).  543 
     544 
  545 







Figure 3. Adhesion of E. coli strains to RWPE-1 cells. A) E. coli expressing type 1 549 
fimbriae. B) E. coli expressing P fimbriae. 550 
          551 
Figure 4. Inhibition effect of xyloglucan (10 mg/ml,) over UPEC adhesion to cell 552 
surface. 4A) Adhesion of E. coli expressing type 1 fimbriae on CacoGoblet . 4B) 553 
Adhesion of E. coli expressing P fimbriae on CacoGoblet. 4C) Adhesion of E. coli 554 
expressing type 1 fimbriae on RWPE-1. 4D) Adhsesion of E. coli expressing P fimbriae 555 
on RWPE-1. 556 




  558 
Figure 5. RWPE-1 Adhesion inhibition. Inhibition produced by propolis (5A) and 559 
hibiscus (5B) at 1 mg/ml over E. coli expressing type 1 fimbriae; and propolis (5C) and 560 
hibiscus (5D) at 10 mg/ml over E. coli expressing P fimbriae. 561 
           562 
          563 
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